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Hypophosphatemia, Hyperphosphaturia, and
Bisphosphonate Treatment Are Associated With Survival
Beyond Infancy in Generalized Arterial Calcification
of Infancy
Frank Rutsch, MD; Petra Bo¨yer, MS; Yvonne Nitschke, MS, Nico Ruf, PhD;
Bettina Lorenz-Depierieux, PhD; Tanja Wittkampf, PhD; Gabriele Weissen-Plenz, PhD;
Rudolf-Josef Fischer, MD, PhD; Zulf Mughal, MBChB, FRCPCH, DCH; John W. Gregory, MD;
Justin H. Davies, MD, FRCPCH, MRCP; Chantal Loirat, MD; Tim M. Strom, PhD;
Dirk Schnabel, MD; Peter Nu¨rnberg, PhD; Robert Terkeltaub, MD; the GACI Study Group
Background—Generalized arterial calcification of infancy has been reported to be frequently lethal, and the efficiency of
any therapy, including bisphosphonates, is unknown. A phosphate-poor diet markedly increases survival of NPP1 null
mice, a model of generalized arterial calcification of infancy.
Methods and Results—We performed a multicenter genetic study and retrospective observational analysis of 55 subjects
affected by generalized arterial calcification of infancy to identify prognostic factors. Nineteen (34%) patients survived
the critical period of infancy. In all 8 surviving patients tested, hypophosphatemia due to reduced renal tubular phosphate
reabsorption developed during childhood. Eleven of 17 (65%) patients treated with bisphosphonates survived. Of 26
patients who survived their first day of life and were not treated with bisphosphonates only 8 (31%) patients survived
beyond infancy. Forty different homozygous or compound heterozygous mutations, including 16 novel mutations in
ENPP1, were found in 41 (75%) of the 55 patients. Twenty-nine (71%) of these 41 patients died in infancy (median,
30 days). Seven of the 14 (50%) patients without ENPP1 mutations died in infancy (median, 9 days). When present on
both alleles, the mutation p.P305T was associated with death in infancy in all 5 cases; otherwise, no clear
genotype-phenotype correlation was seen.
Conclusion—ENPP1 coding region mutations are associated with generalized arterial calcification of infancy in 75% of
subjects. Except for the p.P305T mutation, which was universally lethal when present on both alleles, the identified
ENPP1 mutations per se have no discernable effect on survival. However, survival seems to be associated with
hypophosphatemia linked with hyperphosphaturia and also with bisphosphonate treatment. (Circ Cardiovasc Genet.
2008;1:133-140.)
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Generalized arterial calcification of infancy (GACI,MIM#208000) is a rare autosomal recessive disorder,
reported to date in 180 individuals. Calcification of large-
and medium-sized arteries and marked myointimal prolifer-
ation leading to arterial stenoses are characteristic vascular
features of the GACI phenotype. An extravascular feature,
foci of periarticular calcification, occurs in many of the
affected subjects.1,2 Initial signs of the disease may occur
prenatally,3 and most affected children die in early infancy
from sequelae of vascular occlusion, typically myocardial
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infarction or congestive heart failure due to hypertension.1
Systemic deficiency of nucleotide pyrophosphatase (NPP1)
activity (E.C. 3.6.1.9) leading to low serum and urine inor-
ganic pyrophosphate (PPi) levels has been identified as a
diagnostic hallmark of the disease.4,5 Deficient NPP1-
catalyzed PPi generation in GACI seems to be mediated by
mutations in multiple exons of ENPP1 (MIM*173335).6 This
gene, located on chromosome 6q22-q23, spans 83 kb of
genomic DNA and contains 25 exons.
ENPP1 encodes a type II transmembrane glycoprotein
ectoenzyme that forms homodimers of identical disulfide-
bonded subunits.7 NPP1 has an extracellular catalytic domain
as well as somatomedin B-like and substrate-binding or
substrate-specifying nuclease-like domains.8 NPP1 regulates
soft tissue calcification and bone and joint cartilage mineral-
ization by generating PPi, which not only serves as an
essential physiological inhibitor of hydroxyapatite crystal
growth9 but also is a suppressor of chondrogenesis.10 In artery
smooth muscle cells, deficiencies of NPP1 (or of extracellular
PPi without NPP1 deficiency in ank/ank mice homozygous
for functional inactivation of the PPi transporter ANK)
promote chondrogenic transdifferentiation in vivo and also in
vitro under circumstances where excess of an inorganic
phosphate (Pi) source is provided.10,11 Although the patho-
physiologic role of NPP1-mediated PPi generation in GACI
has come to light within recent years, the factors accounting
for the variation of the GACI phenotype including the
presence or absence of intracerebral artery calcification and
periarticular calcification, early death in utero and long-term
survival are not known.12
PPi and Pi seem to have mutually antagonistic roles in
tissue mineralization.13 Significantly, either a phosphate-poor
diet or crossbreeding with PHEX knockout mice to induce
hypophosphatemia markedly decreased artery calcification
and periarticular calcifications, and increased survival of
NPP1/ and ank/ank mice.14 We previously reported a child
of Turkish descent from a consanguineous marriage who
manifested GACI and periarticular calcifications and was
homozygous for the p.R774C mutation of ENPP1 also
detected on both alleles in his father.6 Strikingly, the father
was not affected by GACI, but suffered from severe hy-
pophosphatemic rickets.6 On the basis of this observation, we
hypothesized that hypophosphatemia may inhibit potential
pathological effects of deficient NPP1-mediated PPi genera-
tion and may prevent humans from developing lethal patho-
logical arterial calcification. Furthermore, within the last few
years, bisphosphonates, which function in part as synthetic
nonhydrolyzeable analogues of PPi,15,16 have been anecdot-
ally reported to have varying degrees of success in the
treatment of GACI.17–19 However, it has been problematic
that information on the clinical, as well as treatment and
outcome features of the majority of cases of GACI comes
from small case reports of one or a handful of patients.
Here, we describe a retrospective, multicenter study of 55
patients with GACI, by far the largest performed to date. In
this study, we characterized subjects for ENPP1 genotype,
and assessed if ENPP1 mutations, bisphosphonate therapy,
and renal phosphate handling and serum phosphate levels
(where specimens were available), were associated with
survival beyond infancy.
Methods
Patients
Inclusion in the study was based on the clinical diagnosis of GACI
and on the availability of DNA material for ENPP1 mutation
analysis. Patient history and clinical data were gathered through a
standardized questionnaire, which was sent to the referring physician
or geneticist. Diagnosis of GACI was based on the presence of
cardiovascular symptoms associated with evidence of arterial calci-
fication with or without periarticular calcification on x-ray or
sonography in infancy,1 or typical histology20 (Figure 1). Diagnosis
of GACI is exemplified in the following case report: The male infant
(case 6 of our study) was born to consanguineous Turkish parents.
The mother is a 20-year-old gravida II, para I, whose first pregnancy
ended with a missed abortion. The father suffers from hypophos-
phatemic rickets since early childhood, presenting with genua vara
and short stature. Pregnancy was complicated by macrosomia of the
fetus and polyhydramnios. The infant was delivered by cesarian
section because of fetal distress. Birth weight was 3070 g, length was
50 cm, and umbilical cord pH was 7.24. Because of respiratory
distress, the infant was intubated and ventilated immediately after
birth. Echocardiography at the first day of life revealed a small
pericardial effusion and increased echogenicity of the walls of the
pulmonary arteries, the aorta, the tricuspid valve, and the coronary
arteries (Figure 1A and 1B). Sonography of the abdomen showed
bright, hyperechogenic walls of the celiac trunc (Figure 1C), the
superior mesenteric artery, and the renal arteries bilaterally. A chest
X-ray showed cardiomegaly, prominent lung vessels, and periartic-
ular calcifications of both shoulders (Figure 1E). Further radiographs
demonstrated irregular calcifications of the left hip and spotted
calcifications in the region of the carpal bones and the carpal joints
(Figure 1D). Serum calcium (2.01 mmol/L) and serum Pi
(1.5 mmol/L) levels were normal. On the basis of the signs of
respiratory distress and pericardial effusion associated with the
presence of arterial and periarticular calcifications, the diagnosis of
GACI was established, and treatment with etidronate 15 mg/kg per
day PO was started at the age of 2 weeks.
Fifty-five patients were included in our study after informed
consent of the parents. The DNA from all patients was subjected to
mutation analysis of ENPP1. The study protocol was approved by
the Muenster University Hospital Ethical Committee and other
participating institutional peer-review human subjects committees.
Of the patients studied, 23 were part of an earlier reported study on
the mutational spectrum of ENPP1 mutations.21
ENPP1 Mutational Analysis
DNA was extracted from EDTA-blood after informed consent. In
specific cases, DNA from blood samples was not available, because
the patients were deceased before the onset of the study and no blood
samples had been taken. In these families, the parents were screened
for mutations, then DNA from the deceased child was extracted from
formalin-fixed tissue blocks and was analyzed to confirm the
segregation of the mutation. With a set of 24 primer pairs, we
amplified all 25 exons and their flanking splice sites of ENPP1 from
genomic DNA by polymerase chain reaction (PCR). The PCR
products were directly sequenced bidirectionally using an ABI 3730
DNA Analyzer and a BigDye Terminator v1.1 Cycle Sequencing Kit
according to the manufacture’s protocol (Applied Biosystems, Foster
City, Calif). All primer sequences are available on request. Muta-
tions were compared with the ENSEMBL polymorphism database.
Statistics
The Kaplan-Meier survival curve was calculated with SPSS soft-
ware. The log-rank test was used to test equality of survival
distributions for the different levels of therapy. The Wilcoxon test for
paired samples was used when comparing serum phosphate levels
and TmP/GFR levels with the respective reference values.
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Results
The study cohort consisted of 55 patients with proven GACI
(28 males and 27 females) of 45 unrelated families. Patients
were included between 2001 and 2006. We included 1
dizygotic pair of twins and 4 monozygotic twins in our
survey. The detailed clinical data on each individual patient
are summarized in Supplemental Table 1 (supplemental
material). Although 36 patients (65.5%) of our study cohort
died in utero or in infancy, 19 patients survived beyond
infancy.
Clinical Features of the GACI Cohort
In 28 of the 55 cases (51%), prenatal signs of the disease were
detected (Supplemental Table 2), with fetal distress, polyhy-
dramnios, and pericardial effusion reported most frequently.
Thirty patients (55%) were delivered prematurely. Five pa-
tients (10%) died in utero and presented as stillbirth. Twenty-
five patients (45%) presented symptoms immediately at birth.
In the remaining 25 patients (45%), no obvious symptoms
were noted immediately at birth. Three infants had appeared
as asymptomatic until the age of 3 to 4 months, when they
presented with failure to thrive, respiratory distress, arterial
hypertension, or heart failure.
Presence of Arterial and Periarticular Calcifications
GACI was suspected during pregnancy in 6 (11%) cases,
when early arterial calcifications were detected by sonogra-
phy. Increased echogenicity of the great vessels was detected
as early as in the 20th gestational week in a fetus. After birth,
arterial calcifications were demonstrated predominantly in
the aorta and in coronary arteries by imaging studies such as
sonography and computed tomography (Supplemental Table
1). Additionally, autopsy, performed in 22 cases (40%),
confirmed calcification of pulmonary and renal arteries in 15
deceased patients. In a subset of 16 patients (29%), periartic-
ular calcifications were noted prenatally or in infancy (Table).
Periarticular calcifications were present in surviving patients
more frequently than in deceased patients.
ENPP1 Mutations in GACI Patients
In 41 (75%) of the patients studied, we detected homozygous or
compound heterozygous mutations in ENPP1. In total, 40
different mutations were detected, including 30 missense muta-
tions, 7 nonsense, and 3 splice site mutations (c.4302TC,
c.565–2AG, c.11642TA). Mutation c.11642TA
leads to skipping of exon 11 causing the frameshift
Figure 1. Characteristic manifestations of
GACI. A through E, Patient 6 in his first week
of age. A, Echocardiogram showing bright
echogenic walls of the aortic arch and
descending aorta (arrows), consistent with aor-
tic calcifications. B, Increased echogenicity of
the aortic root (arrowhead) and left (LCA) and
right (RCA) coronary arteries (arrows). C,
Increased echogenicity of abdominal aorta
(arrows) and celiac trunc (CT) of the same
patient. D, Periarticular calcifications (arrows)
of the carpal joint and around carpal bones of
the left hand. E, Chest x-ray showing moderate
cardiomegaly and periarticular calcifications
(arrows) of both shoulders. F, Cross-section
through the aorta from patient 41, who died
at the age of 6 weeks, showing calcification at
the level of the internal elastic lamina (arrows)
and marked intima proliferation (arrowheads)
(hematoxylin–eosin, 20).
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P365fsX15.21 The mutations were scattered over the whole
coding region of the gene (Figure 2), but most concentrated in
exons encoding the catalytic and the nuclease like domain.
We detected 16 novel mutations (3 nonsense mutations, 11
missense mutations, and 2 splice site mutations; see Figure
2). In 14 (25%) cases, no ENPP1 coding region mutations
were found. These patients did not show any obvious differ-
ence regarding the distribution of the calcifications compared
with the patients with proven ENPP1 mutations (data not
shown). Twenty-nine (71%) of the 41 ENPP1 mutation
positive patients died in infancy (median survival, 30 days),
whereas 7 of the 14 (50%) patients without ENPP1 mutations
died in infancy (median survival, 9 days).
The mutation c.913CA (p.P305T) in exon 8 was detected
most frequently (Figure 2, insert). This mutation was present
on both alleles in 5 unrelated patients, who all died in infancy.
On the other hand, the homozygous mutation c.2320CT
(p.R774C) was associated with a relatively mild phenotype in
1 patient. This mutation was found on 6 alleles in 5 patients
from unrelated 4 families of White origin. Apart from the 4
mutations c.1412AG (p.Y471C), c.1709AG (p.Y570C),
c.2375AG (p.N792S), and c.2713_2717delAAAGA
(p.K905fsX15), which were present in the affected patients of
2 unrelated families, all other mutations were private muta-
tions and presented only in single patients.
Course of GACI in the Study Cohort
Of the 55 patients in this cohort, 6 (11%) cases presented as
stillborns and a total of 30 (55%) patients died within the first
6 months of life despite intensive care therapy, including
ventilatory support. Death was attributed to congestive heart
failure, persistent arterial hypertension, multiorgan failure, or
myocardial infarction. After the age of 6 months, only 1
patient (case 40) died at the age of 7 months within the
observation period (Figure 3A), the eldest living patients
being 21 years old now.
Hypophosphatemia and Renal Phosphate Loss is
Associated With Survival in GACI
Data on serum Pi levels were available from 13 of 19
surviving patients, additional data on maximal renal tubular
phosphate reabsorption were available from 11 of 19 surviv-
ing patients with clinically proven GACI (Figure 4). In 8 of
these patients, serum phosphate levels and TmP/GFR levels
were measured beyond infancy. All these patients showed
Table. Sites of Calcifications Associated With Death and
Survival in 55 GACI Patients
Site of Calcification
Death
(n36)
Survival
(n19)
Aorta 33 (92) 18 (95)
Coronary arteries 30 (83) 8 (42)
Pulmonary arteries 25 (69) 6 (32)
Renal arteries 17 (47) 5 (26)
Periarticular tissue 6 (17) 10 (53)
Data are presented as n (%).
Figure 2. Schematic representation of the human ENPP1 gene and protein with mutations identified in 55 GACI patients. Numbered
boxes represent the 25 exons; patterned boxes represent functional domains. Novel mutations are shown in boldface. Insert at the left
top of the figure shows allele frequency of most common ENPP1 mutations in our study cohort. SO Domain indicates somatomedin
B-like domain. *Splice site mutations c.4302TC and 556–2AG result most likely in exon skipping and hence in frameshifts. †The
mutation P365fsX15 was previously shown to result from skipping of exon 11 caused by the mutation c.11642TA.21
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hypophosphatemia and hyperphosphaturia, which was noted
first between the second and third year of life (Figure 4). In
4 of these children, the urine was also checked for the
presence of microglobulinuria or hyperaminoaciduria, but
these tests yielded normal results. Five patients (cases 8, 15,
16, 43, and 45) were supplemented with phosphate and
calcitriol for signs of hypophosphatemic rickets becoming
apparent between 8 months and 11 years of age, including
bone pain, bowed femora, and short stature. In 1 of these
patients (case 8), phosphate and calcitriol supplementation
was associated with worsening of the arterial stenoses,
therefore treatment for hypophosphatemic rickets was discon-
tinued in this case.
In those patients with hyperphosphaturia, we amplified all
22 PHEX and 3 FGF23 exons by PCR using intronic primers.
PCR products were sequenced bidirectionally. No pathogenic
PHEX or FGF23 mutations were found. Intact FGF23 plasma
levels were measured by ELISA in all patients with hyper-
phosphaturia and were found highly elevated in 2 patients at
1540 pg/mL and 3890 pg/mL, respectively, while on treat-
ment with phosphate and calcitriol (normal range, 10 to 50
pg/mL).25 After a 2-week cessation of calcitriol treatment,
FGF23 levels were only moderately elevated in 1 patient (93
pg/mL; case 15), but still highly elevated in the other patient
(560 pg/mL; case 45).
Bisphosphonate Treatment is Associated With
Survival in GACI
In 17 patients, who survived their first day of life, therapy
with bisphosphonates was instituted (Figure 3B), as etidr-
onate (10 to 20 mg/kg body weight per day PO), pamidronate
(0.1 mg/kg per week up to 5 mg/kg per day IV), clodronate or
risedronate. Bisphosphonate treatment was associated with
survival beyond infancy in 11 (65%) cases, whereas 18 of 26
(69%) patients not treated with bisphosphonates died in
infancy (Figure 3B).
Discussion
GACI was initially held to be a universally fatal disease,1 but
within the last 20 years, anecdotal cases of survival beyond
infancy have been reported.26,27 Although bisphosphonate
therapy has been advocated, it has remained unclear to what
extent such therapy is effective, and predictors of disease
outcome have not previously been defined. This study, albeit
a cross-sectional analysis of subjects referred to a single
international study group, rather than prospective analysis,
clearly indicates GACI to not be an inevitably fatal condition.
Specifically, whereas 36 patients died in utero or within the
critical period of infancy, 19 patients survived beyond in-
fancy and none of the survivors died within the observational
period of 1 to 6 years.
Despite the limitations of the cross-sectional and retrospec-
tive analyses, several factors seemed to be predictive of a
favorable prognosis and survival beyond infancy. First, with
respect to sites of pathological calcifications, subjects who
died in infancy had been reported to suffer from pulmonary,
renal, and coronary involvement more frequently than sur-
viving patients. However, this finding could have been biased
by a higher detection rate of calcifications in these vessels in
autopsy studies rather than in imaging studies performed in
living patients. Taken this bias into account, one cannot
conclude whether the mortality risk depends on specific sites
of calcification or it is more related to the general degree of
calcification.
GACI was observed to be caused by coding region muta-
tions of ENPP1 in 41 (75%) of the cases studied. We did
not exclude ENPP1 deletions or intronic mutations by our
approach. Importantly, GACI survival was not associated
with the presence or absence of ENPP1 mutations per se, but
the presence of the c.913CA (p.P305T) mutation in exon 8
Figure 3. Cumulative survival in GACI patients of our study
cohort. A, Overall survival in all 55 patients, including 12
patients who presented as stillbirths or died before the age of 1
day. B, Survival beyond infancy in 43 patients, who survived
their first day of life, including 17 patients treated with bispos-
phonates compared with 26 patients, who did not receive
bisphosphonate therapy. Patients treated with bisphosphonates
showed significantly increased likelihood of survival (P0.026;
log-rank test).
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on both alleles was always associated with death in infancy
despite any treatment efforts. This mutation affects the
catalytic region of the protein and is conserved across species.
In our study cohort, the p.P305T mutation was the single
most frequently detected mutation, present on 19 alleles of 14
patients (25%) from 10 families. The families carrying this
mutation originated from an Anglo-American background,
suggesting a common founder. Our results suggest the value
of screening specifically for this mutation by PCR in clinical
testing for GACI in the Anglo-American population. On the
other hand, if present on both alleles, the mutation
c.2320CT (p.R774C) was associated with a relatively mild
phenotype in 1 patient. This mutation affecting the nuclease-
like domain of NPP1 was previously shown to be associated
with residual enzyme activity.6 Interestingly, the p.R774C
mutation was also present on both alleles in the father of the
proband. Although the proband was affected by GACI, the
father did not present arterial calcifications in infancy, but
suffered from severe hypophosphatemic rickets since early
childhood.6
Stimulated by observations in 1 human kindred and by
conclusive findings in NPP1 and extracellular PPi-deficient
mice,28 for a protective/compensatory effect of hypophos-
phatemia for clinical phenotype of pathological soft tissue
calcifications in GACI, we focused on available data on
phosphate metabolism in 13 surviving GACI patients. In all
surviving patients tested, serum Pi levels in infancy were
normal, but we noted a decrease of serum Pi levels within the
second year of life, which did not increase as subjects aged.
Decrease of serum Pi levels was associated with a decrease of
renal tubular phosphate reabsorption (TmP/GFR) in these
patients. This effect was not caused by additional PHEX or
FGF23 mutations in these patients. However, in 2 patients,
we detected elevated FGF23 levels (560 pg/mL and 93
pg/mL, respectively), which might at least partially mediate
renal phosphate loss.29
Figure 4. Serum phosphate levels and maximal
renal tubular phosphate reabsorption in
patients with GACI surviving beyond infancy. A,
Serum phosphate levels available from 13 sur-
viving patients. B, TmP/GFR levels available
from 11 surviving patients. Normal serum phos-
phate levels in children between 1 and 3 years
is 1.00 to 1.95 mmol/L, between 4 and 6 years
is 1.05 to 1.80 mmol/L, and between 7 and 9
years is 0.95 to 1.75 mmol/L.22 TmP/GFR was
calculated according to Brodehl et al23 using
the formula TmP/GFRSp(UpScrea)/Ucrea.
Normal TmP/GFR in children between 2 and 15
years is 1.15 to 2.44 mmol/L.24 The means of
serum phosphate levels and the means of
TmP/GFR levels of each surviving patient were
significantly lower than the lowest reference
values in patients older than 3 years of age
(P0.031 for serum phosphate and P0.004
for TmP/GFR levels; Wilcoxon test for 2 paired
samples).
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Hypophosphatemic rickets was documented here in 5
survivors of GACI. Our collective findings suggest that
clinical investigation of the application of a phosphate poor
diet or a phosphate binding agent (eg, lanthanum carbonate,
sevelamer hydrochloride) would be of interest with respect to
early intervention in GACI. NPP1 is not universally ex-
pressed but is present in renal proximal tubule epithelial
cells,30 with unclear functional consequences. We speculate
that NPP1 modulates renal proximal tubule epithelial cell
function. In this context, NPP1 nucleotide pyrophosphatase
activity (E.C. 3.6.1.9) modulates protein glycosylation and
secretion (eg, IgA in plasma cells),31 plays a major role in
proteoglycans sulfation,32 and modulates insulin receptor
signaling.33 Hence, deficient NPP1 expression in renal prox-
imal tubule epithelial cells could modulate the function of
these cells by PPi-independent or PPi-dependent means. With
respect to the latter, PPi seems to antagonize several functions
of Pi and vice versa, including hydroxyapatite crystal growth
in vitro, and architecture and chondrocyte differentiation of
the endochondral growth plate in vivo, and pathological soft
tissue calcification including arterial involvement.13,14 In this
context, it should be noted that tissue and serum levels of PPi
are in the low micromolar range, whereas serum Pi concen-
tration is normally 2 mmol/L in humans and 8 mmol/L in
mice.14 Moreover, a rationale for bisphosphonate therapy
becomes evident for GACI, because bisphosphonates func-
tion in part as nonhydrolyzeable analogues of PPi.
In previous limited case reports, bisphosphonate treatment
had variable success in GACI.17,34 In the current study cohort,
bisphosphonate therapy was associated with survival in 11
(65%) of 17 treated patients, whereas 69% of the patients not
treated with bisphosphonates died. In any retrospective study,
a comparison of these figures with respect to survival is
limited, because the clinical phenotype of the untreated group
was most likely more severe than in the treatment group.
Also, several patients in this study died in utero or immedi-
ately after birth before diagnosis or treatment could be
assigned. On the other hand, 7 patients receiving bisphospho-
nates died within infancy, and also, radiographic resolution of
the calcifications did not prevent the subsequent development
of arterial hypertension. Arterial hypertension might be
caused by microcalcifications not visible on x-ray studies
causing artery wall stiffness. However, we believe that
bisphosphonates promote resolution of calcifications, but fail
to alleviate the associated and often severe myointimal
proliferation that plays a major role in vascular stenoses.
Given that the extent of vascular occlusion has not appeared
to grossly correlate with the extent of calcification in GACI in
the literature,26 and also in some patients included in our
study (patients 8, 32, 33, and 40), direct therapeutic attention
to this aspect of the disorder might improve outcome.
Among the limitations of this study was the inability to
examine serum and urine PPi levels or serum NPP1 protein
levels and associated NPP1 enzyme specific activity, as well
as affected tissue NPP1 mRNA and protein expression. We
did not study other genes encoding mediators of NPP1
expression such as carminerin,35 and regulators of PPi levels
such as ANKH,14 or Pi levels such as TNAP,13 or secondary
determinants of PPi effects on chondro-osseous differentia-
tion of smooth muscle cells such as vanin-1 pantetheinase.11
Nevertheless, the results of this relatively large GACI obser-
vational study indicated that the p.P305T mutation of ENPP1
might serve as a potential tool for genotyping and prognosis.
Furthermore, hyperphosphaturia and hypophosphatemia de-
veloped in some GACI subjects and were associated with
survival beyond infancy, as also was bisphosphonate treat-
ment. Further prospective, controlled studies of bisphospho-
nates and low phosphate dietary or phosphate binding treat-
ment appear indicated for GACI.
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Fam. Pat. Sex Origin affected 
siblings / 
non 
affected 
siblings 
Arterial 
calcific-
ations 
Peri-
articular 
calcific-
ations 
Bisphos-
phonate 
treatment 
Resolution 
of calcific-
ations 
Age at 
data 
collec-
tion 
Age at 
death 
Hypophos-
phatemia* 
Hyper-
phos-
phaturia† 
DNA 
change 
Amino acid 
change 
 
 
Ref. 
 
1 1 m Taiwan  a,c,p,r knees pamidronate \ - 45 days no \ [1,025G>T] 
+ 
[1,112A>T] 
[G342V] + [Y371F] 1  
 2 f Taiwan 2/0 a,c,v shoulder no \ 4 years - \ \ [1,025G>T] 
+ 
[1,112A>T] 
[G342V] + [Y371F]  
2 3 m America   1/0 a,c,r,v no no \ - stillbirth \ \ [913C>A] + 
[913C>A] 
[P305T] +[P305T] 2 
3 4 f GB / 
Nigeria 
2/2 a,c,r no no \ - 8 days no \ [1,831C>G + 
2,002G>A] + 
[2375A>G] 
[L611V + E668K] + 
[N792S] 
3 
 5 f GB / 
Nigeria 
 a,c no pamidronate,  
risedronate 
yes 2 years - no \ [1,831C>G + 
2,002G>A] + 
[2375A>G] 
[L611V + E668K] + 
[N792S] 
 
4 6 m Turkey 1/0 a,c,r hip, 
shoulder, 
wrists 
etidronate yes 8 years - no \ [2320C>T] + 
[2320C>T] 
[R774C] + [R774C] 4 
5 7 f Canada 1/1 a,c,p \ no \ - 15 
minutes 
\ \ [913C>A] + 
[913C>A] 
[P305T] + [P305T]  
6 8 m Turkey 1/3 a,c wrists, 
ankles 
etidronate yes 10 ½ 
years 
- yes yes [2,677G>T] 
+ 
[2,677G>T] 
[E893X] + [E893X] 4,5,6 
7 9 f Italy 1/0 a,c,p soft tissues 
in right axilla 
no \ - 13 days \ \ [1,367G>A] 
+ [?] 
[R456Q] + [2nd 
allele low] 
4 
8 10 m Canada 1/0 a,c no etidronate no - 32 days \ \ [376T>C] + 
[2,176T>C] 
[C126R] + [C726R] 4 
9 11 m GB 1/0 a,c,p,r no \ \ - 1 day \ \ [430+2 T>C 
+ 2,330A>G] 
+ 
[2,330A>G] 
[Splice-Site + 
H777R ] + [H777R] 
 
10 12 m Pakistan 2/3 a,c,p,r,v no no \ - 5 hours \ \ [2,410G>C] 
+ [2,410G>C 
+ 2,462G>A] 
[D804H] + [D804H 
+ R821H] 
7 
 13 f Pakistan  d no no \ - 30 
minutes 
\ \ [2,410G>C] 
+ [2,410G>C 
+ 2,462G>A] 
[D804H] + [D804H 
+ R821H] 
 
11 14 m GB 2 (twins)/0 a,c,p \ \ \ - 6 weeks \ \ [749C>T] + 
[913C>A] 
[P250L] + [P305T] 8 
 15 f GB  a,p \ no spontaneous 16 years - yes yes [749C>T] + 
[913C>A] 
[P250L] + [P305T]  
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12 16 f India 1/0 a, c,p,r,v shoulders, 
elbow, 
wrists, 
knees, 
ankles 
pamidronate, 
etidronate, 
clodronate 
yes 5 years - yes yes [753-
755delATA] 
+ [753-
755delATA] 
[Y252del] + 
[Y252del] 
 
8, 9 
13 17 f Finland 1 / 0 c,r \ \ \ - 4 
months 
\ \ [2,713-
2,717delAA
AGA] + 
[2,713-
2,717delAA
AGA] 
[K905fsX15] + 
[K905fsX15] 
 
14 18 m Ireland 1/0 a,p no no no - 9 days \ \ [913C>A] + 
[913C>A] 
[P305T] + [P305T]  
15 19 m Ireland / 
Philippines 
1/0 a \ pamidronate no 2 years - no \ [1,510A>C] 
+ 
[2,375A>G] 
[S504R] + [N792S]  
16 20 f America 1/0 a,p no \ \ - 25 days \ \ [936T>G] + 
[2375A>G] 
[Y312X] + [N792S] 10 
17 21 f GB 1/0 a,c,r no no \ - 5 
months 
no \ [913C>A] + 
[1,426C>T] 
[P305T] + [R476X] 11 
18 22 m Ireland 1/2 a,c,r,v no pamidronate \ - 4 ½ 
months 
no \ [913C>A] + 
[1499A>C] 
[P305T] + [H500P]  
19 23 m Sweden 1 / 1 d \ \ \ - 1 month \ \ [647C>A] + 
[647C>A] 
[S216Y] + [S216Y]  
20 24 f Germany 1 / 0 a,c,p hips, great 
joints 
no \ - 2 
months 
\ \ [288delG] + 
[2,483-
2,486insATT
C] 
[G96fsX1] + 
[P828fsX12] 
 
21 25 m France 2 / 1 a,p yes no \ - stillbirth \ \ [826G>A] + 
[1,412A>G] 
[D276N] + [Y471C]  
 26 m France  a,c,p \ pamidronate  
etidronate 
\ - 12 days no no [826G>A] + 
[1,412A>G] 
[D276N] + [Y471C]  
22 27 f Italy 1 / 0 d no pamidronate no - 2 
months 
\ \ [1,538A>G] 
+ 
[1,976A>G] 
[Y513C] + [Y659C]  
23 28 m GB 2/0 a,c,p \ bisphosphonate \ - 12 hours \ \ [783C>G] + 
[878-
879delAA] 
[Y261X] + 
[K293fsX3] 
8 
 29 m GB 2/0 a no no \ 5 1/2 
years 
- yes yes [783C>G] + 
[878-
879delAA] 
[Y261X] + 
[K293fsX3] 
 
 
24 30 f GB 1/0 d,c,p no \ \ - 16 
weeks 
\ \ [556-2A>G] 
+ [913C>A] 
[Splice-Site] + 
[P305T] 
 
25 31 m Ireland 1/0 a,c,v no pamidronate yes 2 1/2 
years 
- no \ [2,320C>T + 
2,662C>T] + 
[2,375A>G] 
[R774C + R888W] 
+[N792S] 
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26 32 
 
f Italy / 
Germany-
America 
2 /0 a,p,v shoulders, 
hip, knee 
no spontaneous 14 1/2 
years 
- yes yes [913C>A] + 
[1,164+2T>
A] 
[P305T] 
+[P365fsX15] 
12, 13 
 33  f Italy / 
Germany-
America 
 a,v no \ spontaneous 6 years - no no [913C>A] + 
[1,164+2T>
A] 
[P305T] 
+[R364fsX15] 
 
 
27 34 f German 1/3 a,c,r \ \ \ - 1 month \ \ [1,072-
1,082delCA
GCTTCCTA
A] + 
[1,737G>C + 
2,320C>T] 
[Q358fsX1] + 
[L579F] +[R774C] 
4 
28 35 m America 1/0 a,r,v hip, elbows, 
wrists 
\ \ 3 years - \ \ [1,046G>A] 
+ 
[1,709A>G] 
[R349K] + [Y570C] 14 
29 36 f Australia 1/0 a,p no \ \ - 9 hours no \ [1,412A>G]+ 
[1,709A>G] 
[Y471C] + [Y570C]  
30 37 f America 2 (twins)/ 
1 
c,r no \ \ - 3 
months 
no \ [913C>A] + 
[2,320C>T + 
2,662C>T] 
[P305T] + [R774C + 
R888W] 
 
31 38 m America 2 /0 
(prenatal 
diagnosis 
in 2nd 
child) 
a,c \ \ \ - 3 
months 
\ \ [725G>A] + 
[1,441C>T] 
[G242E] + [R481W]  
32 39 f America/ 
Ireland 
2/3 d,p no no \ - 1 hour \ \ [913C>A] + 
[913C>A] 
[P305T] + [P305T] 8, 15 
 40 f America/ 
Ireland 
 a,c,r,v no etidronate yes - 7 ½ 
months 
no \ [913C>A] + 
[913C>A] 
[P305T] + [P305T] 16 
33 41 m America 1/0 a,c,p no  \ - 6 weeks \ \ [1,441C>T] 
+ [2,713-
2,717delAA
AGA] 
[R481W] 
+[K905fsX15] 
4 
34 42 f America 1 / 2 d \ no \ - 9 days \ \ - - 4 
35 43 m Germany 1 / 1 v hip, shoulder \ \ 15 years - yes yes - -  
36 44 m Turkey 1 / 1 a,c,r wrists etidronate yes 4 years - no \ - - 17 
37 45 m Pakistan 2 / 3 a,p,v hips, 
shoulders 
no spontaneous 17 years - yes yes - -  
38 46 m France 1 / 0 a,c,p shoulder, hip no \ - stillbirth \ \ - -  
39 47 m Latin 
America 
1 / 2 d multiple 
sites 
etdironate yes 3 3/4 
years 
- \ \ - -  
40 48 f Turkey 1(twin) / 2 a,p,v no ? \ - 9 days \ \ - -  
 
41 49 f Turkey 1 / 2 a,p,v shoulder, 
ankle 
no \ - stillbirth \ \ - -  
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42 50 f Canada 1 / 0 a,c,p,r no no \ - 6 ½ 
weeks 
\ \ - - 4, 18 
43 51 m America 2 (twins)/ 
0 
a,c,p no no \ 7 years 5 
months 
\ \ - - 19 
 52 m America  a,p no no spontaneous - - \ \ - -  
44 53 m India 1 / 0 c no no \ - stillbirth \ \ - -  
45 54 f Belgium 2 (twins) 
/0 
a,v no etidronate yes 21 years - no \ - - 4, 20 
 55 f Belgium  a,v no etidronate yes 21 years - no \ - -  
 
Supplemental table 1. Clinical and mutational data on 55 individual patients with generalized arterial calcification of infancy. 
m= male, f=female, a=aorta, c=coronary arteries, p=pulmonary artery, r=renal artery, v=heart valves, d= diverse arteries throughout 
the body. “\”= no data available.  
Novel mutations are noted in bold face. 
*Hypophosphatemia was diagnosed if serum phosphate levels were below the reference range (between 1 and 3 years: 1.00-1.95 
mmol/l, between 4 and 6 years: 1.05-1.80 mmol/l, between 7 and 9 years: 0.95-1.75 mmol/l).21 
†Hyperphosphaturia: TmP/GFR was calculated according to the formula TmP/GFR = Pp- Up x Pcrea    .22
                                                                                                                                                 Ucrea              
Hyperphosphaturia was diagnosed if TmP/GFR was below 1.15 mmol/l in patients between 1 and 12 years.23
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Symptom Prenatal period Neonatal period Infancy 
 Overall Death 
(n=36) 
Overall 
Survival (n=19)
Overall Death 
(n=36) 
Overall Death 
(n=36) 
Pleural effusion 4   (11%) 2   (5%) 1 (3%) 
Ascites 5   (14%) 2   (5%) 1 (3%) 
Pericardial 
effusion 
8   (22%) 3   (8%) 1 (3%) 
Fetal hydrops 7   (19%) 3   (8%) / 
Decreased fetal 
movements 
3   (8%) / / 
Fetal distress 8   (22%) / / 
Polyhydramnios 10 (28%) / / 
Respiratory 
distress 
/ 15 (42%) 2 (5,5%) 
Cardiac 
insufficiency 
/ 22 (61%) 6 (17%) 
Arterial 
hypertension 
/ 10 (28%) 2 (5,5%) 
Impalpable 
pulses 
/ 
0 (0%) 
0 (0%) 
3 (16%) 
 
0 (0%) 
1 (5%) 
 
6 (31,5%) 
2 (10,5%) 
/ 
 
/ 
 
/ 
 
/ 3 (8%) 
Overall 
Survival (n=19)
0 (0%) 
1 (5%) 
2 (10,5%) 
 
1 (5%) 
/ 
 
/ 
/ 
7 (37%) 
 
8 (42%) 
 
5 (26%) 
 
4 (21%) 0 (0%) 
Overall 
Survival (n=19)
0 (0%) 
0 (0%) 
0 (0%) 
 
/ 
/ 
 
/ 
/ 
0 (0%) 
 
0 (0%) 
 
8 (42%) 
 
1 (5%) 
 
Supplemental table 2. Symptoms recorded in utero, within the neonatal period and later in infancy associated with death  
and survival in 55 patients with GACI. Prenatal symptoms were detected by sonography during pregnancy.  
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